Bristol Candidate Reduces Lung Function Decline in Pulmonary Fibrosis

 Phase 2 study shows 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 62% relative reduction in the rate of decline in percent predicted forced vital capacity (ppFVC) versus placebo

BMS-986278 was well tolerated with rates of adverse events and treatment discontinuation comparable to placebo

Data demonstrate potential of BMS-986278 in pulmonary fibrosis and support progression into Phase 3

https://www.businesswire.com/news/home/20230519005266/en/Bristol-Myers-Squibb%E2%80%99s-Investigational-LPA1-Antagonist-Reduces-the-Rate-of-Lung-Function-Decline-in-Patients-with-Idiopathic-Pulmonary-Fibrosis